Presentation + Paper
12 March 2024 Addition of an ECM remodeling drug improves target engagement of immunotherapy in solid pancreatic cancer tumors
Cody C. Rounds, Dalliya Rabei, Jasmine Williams, Sanzida Haque, Dhruv Ranjan, Chengyue Li, Richard Cisek, Rama Madhurapantula, Danielle Tokarz, Thomas Irving, Marcella Vaicik, Kenneth M. Tichauer
Author Affiliations +
Abstract
Pancreatic ductal adenocarcinoma continues to be one of the most lethal cancers today with an abysmal ~8% 5-year survival rate that has remained relatively constant over time. This is thought to be largely due the desmoplastic stroma in the extracellular matrix of these tumor types, inhibiting both the penetration as well as target engagement of treatments. Here we present a methodology for evaluating a monoclonal antibody’s drug target engagement in the presence of an extracellular matrix remodeling drug using paired-agent imaging principles and a subcutaneous tumor mouse model.
Conference Presentation
(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.
Cody C. Rounds, Dalliya Rabei, Jasmine Williams, Sanzida Haque, Dhruv Ranjan, Chengyue Li, Richard Cisek, Rama Madhurapantula, Danielle Tokarz, Thomas Irving, Marcella Vaicik, and Kenneth M. Tichauer "Addition of an ECM remodeling drug improves target engagement of immunotherapy in solid pancreatic cancer tumors", Proc. SPIE 12821, Visualizing and Quantifying Drug Distribution in Tissue VIII, 1282102 (12 March 2024); https://doi.org/10.1117/12.3002624
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Collagen

Pancreatic cancer

Mouse models

Back to Top